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 Abstract 
  Background/Aims:   The ideal hemoglobin target in chronic kidney disease remains unknown. 
Ultimately, individualized targets may depend upon the properties of the patient’s endothelial 
and vascular milieu, and thus the complex relationships between these factors need to be fur-
ther explored.   Methods:   F orty-six patients with a glomerular filtration rat e ( GF R )   ! 30  ml/
min/1.73 m  2   or on renal replacement therapy underwent measurement of hemoglobin, endo-
thelial microparticles (EMPs) and aortic pulse wave velocity (PWV) at 0, 3 and 6 months. In ad-
dition, a number of inflammatory, cardiac and vascular biomarkers were measured at baseline. 
  Results:  No correlation was observed between baseline values of PWV and EMPs, PWV and he-
moglobin, or hemoglobin and EMPs in the overall cohort. When stratified by CKD status, a pos-
itive correlation was observed between PWV and EMP CD41–/CD144+ in patients with GFR  ! 30 
ml/min/1.73 m  2   only (r = 0.54, p = 0.01). Asymmetric dimethylarginine correlated with baseline 
PWV (r = 0.27, p = 0.07), and remained significantly correlated with the 3- and 6-month PWV 
measurement.  Conclusions:  In this small heterogeneous cohort of dialysis and non-dialysis pa-
tients, we were unable to describe a physiologic link between anemia, endothelial dysfunction 
and arterial stiffness.    Copyright © 2011 S. Karger AG, Basel 
  Published online: November 4, 2011 
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 Introduction 
 Anemia related to chronic kidney disease (CKD) may contribute to endothelial dysfunc-
tion through a decrease in shear stress, as physiologic laminar fluid shear stress is crucial for 
normal vascular function and structure   [1, 2]  . Anemia in CKD patients is also associated 
with arterial stiffness   [3]  . However, despite the potential ‘endothelial benefit’ of increasing 
hemoglobin in CKD patients, hemoglobin normalization is associated with a poor clinical 
outcome   [4–7] .
    Endothelial dysfunction has been shown to be an important component of vascular dis-
ease in CKD patients  [8, 9] . Endothelial microparticles (EMPs) are small ( ! 1   m in diameter), 
non-nucleated phospholipid vesicles shed from the endothelial cell membrane in states of en-
dothelial activation or apoptosis and express on their cell surface various antigens specific to 
the state of their parental endothelial cell   [10, 11]  . Given technological advances, we are now 
able to measure EMPs and thus ‘quantify’ the phenomenon of endothelial dysfunction   [12]  .
    EMPs have been demonstrated to be elevated in a variety of clinical states characterized 
by vascular disease and have been identified in those with CKD   [13–18]  . EMPs have been 
shown to correlate with indices of arterial stiffness in hypertension and end-stage renal dis-
ease, suggesting a possible role of EMPs in the vascular disease process   [18, 19]  .
    We sought to further explore the relationship between EMPs, hemoglobin and arterial 
stiffness (measured by aortic pulse wave velocity, PWV) as a preliminary step in approach-
ing the clinical dilemma of anemia management and endothelial health in CKD patients.
    Study Design and Methods 
 This prospective observational study was undertaken at a single tertiary-care institution, 
St. Paul’s Hospital, between January 2008 and January 2009. The study measured both PWV 
and EMP at 0, 3 and 6 months. At baseline, blood tests for conventional tests and specific bio-
markers were included. All subjects were studied without discontinuation of any medication.
  We included patients on dialysis (conventional hemodialysis, HD, or peritoneal dialysis, 
PD) and those not on dialysis with estimated glomerular filtration rate (eGFR)   ! 30  ml/
min/1.73 m  2   for   1  6 months. Those on dialysis required stable access for 3 months and all 
required stable hemoglobin for 2 months ( 8 10 g/l). Exclusion criteria included a known dys-
rhythmia, dementia and clinical inability to comply with testing. Subjects with previous re-
nal transplant were also excluded. This study received institutional ethics approval and ad-
hered to the Declaration of Helsinki. All patients provided informed consent.
    Clinical and Laboratory Variables 
  Data collection included demographic and clinical variables, and ‘usual’ conventional 
blood work values (i.e. white blood cell count, WBC, hemoglobin, iron saturation, calcium, 
phosphate, parathyroid hormone, albumin, HbA  1C  , total cholesterol, triglycerides, low-den-
sity lipoprotein and high-density lipoprotein). In order to minimize blood drawing, the 
blood work values were taken from the patient records closest to the date of the first PWV 
measurement (  8 3  months).
    At baseline, each subject had the following biomarkers measured: pro-inflammatory in-
terleukin (IL)-18 (MBL, Nagoya, Japan; detection limit: 12.5 pg/ml), anti-inflammatory IL-10 
(R&D Systems, Minneapolis, Minn., USA; detection limit: 3.9 pg/ml), calcification inhibitor 
fetuin A (Alpco Diagnostics, Salem, N.H., USA; detection limit: 0.05 g/l), endogenous com-
petitive inhibitor of nitric oxide synthase asymmetric dimethylarginine (ADMA; Alpco Di-
agnostics; measured by competitive ELISA method; detection limit: 0.05   mol/l), highly sen-192
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sitive C-reactive protein (hs-CRP; Siemens BN-II nephelometer CardioPhase hsCRP method; 
detection limit: 0.175 mg/l), B-natriuretic peptide (Siemens Centaur immunoassay analyzer; 
detection limit: 2 pg/ml) and troponin I (Siemens Centaur immunoassay analyzer; detection 
limit: 0.02     g/l). These biomarkers were selected on the basis of assay robustness, linkage to 
known pathophysiologial processes presumed to be important in structural and functional 
vascular changes, and known association in CKD populations to portend increased morbid-
ity and mortality. HD patients had blood work drawn prior to a mid-week dialysis session, 
and CKD and PD patients had blood sampled during routine outpatient clinic visits.
  Endothelial  Microparticles 
  We measured the following EMPs: CD41–/CD144+, a specific EMP, CD41–/CD144+/
CD31+, a marker of endothelial apoptosis, and CD62E+, a marker of endothelial activation. 
   Preparation of Platelet-Free Plasma for EMP Analysis.   Within 1 h of collection, citrated 
blood was spun at 1,500   g   for 15 min at room temperature. The platelet-poor plasma was 
carefully removed and further spun at 12,700   g   for 10 min at room temperature to obtain 
platelet-free plasma. The platelet-free plasma was stored at –80    °   C for future flow-cytometric 
characterization and enumeration of EMP subpopulations.
   Flow-Cytometric Characterization and Enumeration of EMP Subpopulations.  Undiluted 
platelet-free plasma (100     l) was incubated at room temperature for 30 min with the follow-
ing antibodies or their respective isotype controls: CD31-FITC, clone WM59 (BD Bioscience, 
catalogue No. 555445), CD144-PE, clone TEA1/31 (Beckman Coulter, catalogue No. A07481), 
CD41-PC5, clone P2 (Beckman Coulter, catalogue No. 6607116), IgG  1  -FITC (Dako, cata-
logue No. X0927), IgG  1  -RPE (Dako, catalogue No. X0928), IgG  1  -RPECy5 (Dako, catalogue 
No. X0955) and CD62E-PE, clone 68-5H11 (BD Bioscience, catalogue No. 551145). Following 
incubation with antibodies, flow count beads (100     l; Beckman Coulter, catalogue No. 
7547053) were added to each sample and analysis immediately performed using a MoFlo 
high-speed cell sorter (Beckman Coulter). A forward and side scatter dot plot was used to 
determine analysis regions while running microspheres of known size (0.5 and 1.0    m). 
EMPs were defined as events   ! 1     m in size and expressing the antigens CD41–/CD144+. 
EMPs were further investigated for their CD31 expression, or lack thereof. Separately, 
CD62E+ MPs were quantified. The number of EMPs per microliter was calculated as per the 
manufacturer specifications: absolute EMP count (n/    l) = (total number of MPs counted/
total number of beads counted)   !   flow count beads assayed per concentration. Flow Check 
high-intensity alignment grade 1.0- and 0.5-    m particles were obtained from Polysciences 
(catalogue Nos. 23517-10 and 23516-10, respectively).
  PWV  Measurements 
 Aortic PWV measurements were performed using the SphygmoCorCV MS (version 8.0; 
AtCor Medical, Sydney, N.S.W., Australia) by three trained individuals (C.W., M.S. and Lina 
Sioson). We have previously demonstrated excellent interobserver agreement   [20]  . In HD 
patients, measurements were taken immediately prior to their ‘mid-week’ dialysis session, 
i.e. on Wednesday if their schedule was Monday/Wednesday/Friday. CKD and PD patients 
(with an indwelling access) had these measurements performed during their routine outpa-
tient clinic visits.
  Objectives  and  Hypothesis 
 Our primary objective was to explore the relationships between the following three vari-
ables: EMPs, hemoglobin concentration and arterial stiffness (measured by PWV). We hy-
pothesized that we would observe a positive association between EMPs and PWV, and in-
verse associations between hemoglobin and PWV and hemoglobin and EMPs.193
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    Our secondary objectives were to explore the relationship between the biomarkers mea-
sured and PWV. We hypothesized that biomarkers of inflammation and cardiovascular dis-
ease will be correlated with aortic stiffness. 
    We stratified the baseline data and serial EMP and PWV measurements by CKD status 
to highlight differences between groups.
  S t a t i s t i c s  
 Demographic variables for the study cohort were summarized as follows: for categorical 
variables, the frequency and percentage are recorded, and differences are measured using the 
    2   test; for normally distributed continuous variables, the mean   8   SD is recorded and dif-
ferences are measured using a t test; for not normally distributed continuous variables, the 
median (interquartile range, IQR) is given, and differences are measured using the non-
parametric Wilcoxon signed-rank test. Normality of the underlying distributions of the con-
tinuous variables of interest was assessed using the Shapiro-Wilk test for normality. The co-
hort was divided into two groups according to CKD status: those requiring a form of renal 
replacement therapy (RRT) and those with CKD not yet on dialysis. Associations between 
PWV and EMPs were assessed using Pearson’s correlation coefficients. A value of p   !   0.05 
was regarded as statistically significant. The statistical software programs used were SAS, 
version 9.1 (SAS Institute, Cary, N.C., USA) and S-PLUS 7.0.
  R e s u l t s  
  The study cohort was recruited from 500 patients on HD or PD, or patients with a GFR 
  !  30 ml/min/1.73 m  2   at the time of enrollment. Of these, n = 410 were not eligible due to re-
cent initiation (  !  6 months) of RRT, recent vascular access creation (  !  3 months), unstable 
hemoglobin level, known dysrhythmia or dementia. This left 90 patients eligible for enroll-
ment, and a total of 46 patients consented to participate in the study.
    Fifty-four percent of the patients were on RRT with a median dialysis vintage of 1,057 
days (643–1,400), the rest were CKD subjects not yet on dialysis.  Table 1  displays the baseline 
demographic and clinical variables stratified by CKD status. Medication use at baseline was 
the only difference between groups. Of note, 32 subjects (70%) were receiving treatment with 
an erythropoietin-stimulating agent (ESA) at baseline.  Table 2  outlines laboratory and PWV 
values stratified by CKD status. Hemoglobin levels were different between the CKD and di-
alysis group (116 vs. 122 g/l, p = 0.06,). In addition, patients on dialysis had a higher WBC, 
phosphate and parathyroid hormone level, while their albumin level was lower compared to 
CKD patients (  table 2  ). CRP, IL-18 and troponin I levels were increased, and fetuin A level 
was decreased in the dialysis group (  table 2  ).
    Baseline EMP Levels, Hemoglobin Concentration and PWV 
  Patients on dialysis had quantitatively higher values of EMPs and PWV compared to 
CKD patients, although these differences were not statistically significant ( table 2 ). Baseline 
PWV for the entire cohort is displayed in   figure 1  . In the overall cohort, there was no cor-
relation between baseline PWV and EMPs measured (data not shown), baseline PWV and 
hemoglobin (r = –0.07, p = 0.66), or hemoglobin and EMPs measured (data not shown). 
When the data were stratified by CKD status, there was a positive correlation between PWV 
and EMP CD41–/CD144+ in the CKD patients only (r = 0.54, p = 0.01), and the expected 
relationships between the latter two correlations, respectively, although non-significant 
(  fig. 2  ). In the dialysis group, there were no significant correlations between any of these 
variables.194
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Table 1. B  aseline demographic and clinical variables according to renal disease stage
Variable CKD
(n = 21; 46%)
Dialysis
(n = 25; 54%)
p 
value
Age, years 68813 65813 0.49
Males, n (%) 13 (62) 19 (76) 0.30
Caucasians, n (%) 14 (67) 12 (48) 0.20
SBP, mm Hg 128814 128822 0.90
DBP, mm Hg 73811 73812 0.98
Pulse pressure, mm Hg 55 (48–61) 56 (41–67) 0.86
Weight, kg 73814 72.5812 0.84
Height, cm 173 (157–179) 171 (163–177) 0.92
Body mass index 25.283.0 25.383.6 0.91
Primary renal disease, n (%)
Diabetes 5 (24) 7 (29) 0.66
Renal vascular disease 6 (28) 5 (21)
Hereditary causes 2 (10) 1 (4)
GN and vasculitis 3 (14) 7 (29)
Others 4 (19) 4 (17)
Unknown 1 (5) 0
Co-morbid disease, n (%)
Diabetes 4 (19) 8 (32) 0.32
Hypertension 18 (86) 22 (88) 0.82
Dyslipidemia 0 1 (4) 0.35
Current smoker 1 (5) 2 (8) 0.66
Cerebral vascular disease 0 2 (8) 0.19
Cardiovascular disease 8 (38) 11 (44) 0.69
Peripheral vascular disease 4 (19) 3 (12) 0.51
Myocardial infarction 4 (19) 4 (16) 0.79
CABG 4 (19) 3 (12) 0.51
Congestive heart failure 5 (24) 5 (20) 0.76
Ischemic heart disease 5 (24) 10 (40) 0.24
Medications, n (%)
Phosphate binders 13 (62) 25 (100) 0.0007
Vitamin D 14 (67) 15 (60) 0.64
ACEI 5 (24) 11 (44) 0.15
Angiotensin receptor blocker 11 (52) 3 (12) 0.003
Statins and Ezetrol 14 (67) 17 (68) 0.92
-Blockers 12 (57) 11 (44) 0.37
Calcium channel blockers 10 (48) 2 (8) 0.002
Iron, n 12 (57) 23 (92) 0.006
p.o. 12 9 0.0005
i.v. 0 14
ESA
Eprex, n (%) 6 (29) 20 (80) 0.0005
Weekly dose, IU 2,297 (2,000–2,997) 5,296 (4,331–7,998) 0.06
Aranesp, n (%) 2 (10) 4 (16) 0.52
Weekly dose, IU 13.48810.59 19.8389.46 0.49
Re  sults are displayed as percentages where indicated, or means 8 SD and medians (IQR), depending 
on the underlying data distribution. ACEI = Angiotensin-converting enzyme inhibitor; CABG = corona-
ry-artery bypass graft; GN = glomerulonephritis; SBP/DBP = systolic/diastolic blood pressure.195
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    Follow-Up EMP Levels, Hemoglobin Concentration and PWV 
  At 3 and 6 months, there were no significant differences between PWV or EMP levels 
between groups, although the same trend to higher quantitative values was observed in the 
dialysis group (  table 3  ). Likewise, a significantly lower hemoglobin level was observed in the 
dialysis group at 3 and 6 months. No correlation was observed between 3- or 6-month PWV 
and EMP values, PWV and hemoglobin, or EMPs measured and hemoglobin (data not 
shown).
  Biomarkers  and  PWV 
  Only ADMA correlated with baseline PWV (r = 0.27, p = 0.07), and this correlation re-
mained significant at the 3- (r = 0.43, p = 0.01) and 6-month measurements of PWV (r = 0.40, 
p = 0.01).
  C l i n i c a l   O u t c o m e s  
  In the 6 months following the first PWV measurement, there were no clinical cardio-
vascular disease events recorded for the entire cohort; 1 subject died, and 2 patients under-
went renal transplantation.
Table 2. B  aseline laboratory and PWV values according to renal disease stage
Variable CKD
(n = 21; 46%)
Dialysis




WBC, !109/l 6.5 (5.3–7.5) 8.1 (6.5–8.7) 0.03
Hemoglobin, g/l 122811 116811 0.06
Calcium, mmol/l 2.30 (2.27–2.43) 2.37 (2.27–2.42) 0.91
Phosphate, mmol/l 1.380.2 1.580.3 0.02
Albumin, g/l 42 (41–44) 40 (36–42) 0.007
Parathyroid hormone, pg/ml 17 (11–30) 33 (18–48) 0.04
HbA1C, % 6.381.1 6.581.0 0.79
Total cholesterol, mmol/l 4.1380.88 3.9481.02 0.56
Triglycerides, mmol/l 1.41 (0.80–1.65) 1.50 (1.30–2.05) 0.33
High-density lipoprotein, mmol/l 1.05 (0.87–1.40) 0.92 (0.83–1.31) 0.63
Biomarkers
BNP, pg/ml 106 (35–141) 160 (71–606) 0.08
CRP, mg/l 1.7 (0.6–3.3) 6.0 (2.4–12.5) 0.003
Serum IL-10, pg/ml 10.7 (7.9–13.2) 14.1 (11.0–18.3) 0.04
Serum IL-18, pg/ml 301 (251–417) 374 (251–584) 0.11
ADMA, mol/l 0.62 (0.57–0.68) 0.65 (0.59–0.74) 0.56
Fetuin A, g/l 0.37 (0.32–0.41) 0.31 (0.26–0.37) 0.01
Troponin I, mmol/l 0.02 (0.02–0.02) 0.03 (0.02–0.04) 0.04
Microparticles, n/l
CD41–/CD144+  34 (20–84) 51 (29–93) 0.46
CD41–/CD144+/CD31+  7.9 (4.6–13.0) 11.3 (4.0–15.3) 0.55
CD62E+  66 (34–138) 95 (45–194) 0.20
P WV,  m/s 9.9 (8.5–13.1) 11.4 (9.7–13.1) 0.22
Re  sults are displayed as means 8 SD or medians (IQR), depending upon the underlying distribution 
of data. BNP = B-natriuretic peptide;196
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  Discussion 
  The purpose of this study was to explore the relationship between EMPs, hemoglobin 
and arterial stiffness as a preliminary step in understanding the relationship between anemia 
management and endothelial health in CKD patients. By stratifying the cohort by CKD sta-
tus, we were able to demonstrate several differences in medication use and conventional 
laboratory values at baseline, and a gradation in severity of biomarkers of ‘inflammation’ and 
‘endothelial health’ which persisted over time. While we were unable to find any relationship 
between EMPs, hemoglobin concentration and arterial stiffness in the overall cohort, there 
was, however, a positive correlation between PWV and EMP CD41–/CD144+ in CKD pa-
tients. 
  Fig. 1.   PWV in the entire co-
hort. Distribution of PWV is 
slightly skewed to the right; 
median 11.1 m/s, (IQR: 8.8–
13.1 m/s). 
  Fig. 2.   Relationships between 
hemoglobin, EMP and PWV. 
3D plot demonstrating rela-
tionships between variables of 
interest. Correlations (Pear-
son) between hemoglobin, 
CD41–/CD144+ EMP and 
PWV are indicated under-
neath, stratified by CKD sta-
tus. Note: only in the CKD 
(not yet on dialysis) subgroup, 
there is a significant correla-
tion between EMP and PWV. 197
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    Similar blood pressure values were observed between groups at baseline, although a 
higher percentage of the CKD group was prescribed anti-hypertensives (specifically angio-
tensin receptor blockers and calcium channel blockers). More patients in the dialysis group 
were prescribed ESAs, iron and phosphate binders; despite this, they had a lower mean he-
moglobin concentration (116 vs. 122 g/l, p = 0.06), higher serum phosphate (1.5 vs. 1.3 
mmol/l, p = 0.02) and higher intact parathyroid hormone (33 vs. 17 pg/ml, p = 0.04), re-
spectively. This observation likely relates to several factors in favor of the CKD group, in-
cluding the maintenance of intrinsic erythropoietin and phosphate excretion, the absence 
of frequent blood loss (blood sampling/HD tubing) and lower degrees of inflammation. 
Consistent with this observation are the significantly higher levels of WBC, lower albumin 
and higher CRP, IL-10 and troponin I levels in those on dialysis compared to the CKD 
group. In fact, all the biomarkers assessed were quantitatively higher in those on dialysis, 
alluding to a greater severity of inflammation, cardiac disease and worse vascular health 
in this group.
    PWV was higher (11.4 vs. 9.4 m/s, p = 0.22) in the dialysis group, although it was not 
statistically significant given the small sample size. In larger studies, this 2 m/s difference has 
been shown to portend higher risk and, therefore, is likely of clinical importance. The levels 
of the EMPs CD41–/CD144+ (specific EMP), CD41–/CD144+/CD31+ (marker of endothelial 
apoptosis) and CD62E+ (marker of endothelial activation) were also quantitatively higher in 
those on dialysis (non-significant). While EMP levels have been shown to increase with CKD 
severity in children, the same has not been shown in adults  [16, 17] . This may reflect the com-
Table 3. F  ollow-up data according to renal disease stage
Variable CKD
(n = 21; 46%)
Dialysis




Baseline 9.9 (8.5–13.1) 11.4 (9.7–13.1) 0.22
3 months 9.9 (9.1–14.0) 11.5 (9.5–13.4) 0.50
6 months 9.9 (7.4–12.4) 11.1 (7.9–13.3) 0.52
Microparticles, n/l
CD41–/CD144+ 
Baseline 34 (20–84) 51 (29–93) 0.46
3 months 26 (20–48) 51 (31–71) 0.09
6 months 43 (21–84) 50 (35–81) 0.15
CD41–/CD144+/CD31+ 
Baseline 7.9 (4.6–13.0) 11.3 (4.0–15.3) 0.55
3 months 6.7 (2.1–10.3) 8.3 (3.9–11.5) 0.38
6 months 8.8 (6.5–16.1) 6.0 (2.6–14.1) 0.19
CD62E+ 
Baseline 66 (34–138) 95 (45–194) 0.20
3 months 66 (32–94) 138 (71–217) 0.07
6 months 81 (59–159) 109 (70–184) 0.33
Hemoglobin, g/l
Baseline 122811 116811 0.06
3 months 12089 11289 0.01
6 months 12489 112810 0.0004
Res  ults are displayed as means 8 SD or medians (IQR), depending on the underlying distribution of 
data.198
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peting co-morbidities that lead to endothelial dysfunction and vascular disease in the latter 
group, regardless of dialysis status.
    In agreement with others, we were able to demonstrate a relationship between arterial 
stiffness and EMPs, however only in our CKD patients   [17, 18]  . Other studies have been able 
to describe associations between PWV, EMP and hemoglobin in patients with CKD, includ-
ing those on dialysis. Boulanger et al.   [21]   elegantly demonstrated an inverse correlation be-
tween both EMP CD144+ (specific EMP) and CD41–/CD31+ (marker of apoptosis) and shear 
stress in the brachial artery related to anemia of CKD in dialysis patients. Verbeke et al.   [22]   
demonstrated that by increasing hemoglobin from 94 to 120 g/l with iron   8   ESA in 10 HD 
patients, shear stress increased and brachial-artery stiffness decreased. Concordant with 
these findings, a negative association between hemoglobin concentration and arterial stiff-
ness measured by PWV was reported in a cohort of dialysis patients, suggesting that as he-
moglobin increases, endothelium health improves   [3]  .
    There may be a number of reasons for the absence of an association between hemoglo-
bin, PWV and EMP in the present study related both to measurement techniques as well as 
the cohort itself. Firstly, different techniques were used to measure arterial stiffness, i.e. 
PWV versus brachial-artery stiffness   [21, 22]   versus flow-mediated dilatation   [18]  . In addi-
tion, the patients in the current study were very well and clinically stable (low mortality rate 
and stable PWV and EMP levels over time) and did not represent a wide range of hemoglobin 
concentrations. We believe that these factors likely affected our ability to detect a relation-
ship between hemoglobin and PWV in a relatively small number of individuals. However, 
we may have learned about vascular health indirectly from this cohort, given these features 
(i.e. that it can be maintained in the presence of clinical stability and stable hemoglobin).
    Of all the biomarkers measured, only ADMA correlated with PWV-measured arterial 
stiffness. ADMA is an inhibitor of nitric oxide synthase and has been shown to acutely in-
crease arterial stiffness when infused into healthy subjects   [23]  ; it is a strong predictor of 
cardiovascular events and death in CKD patients   [24]  .
    There are several limitations in our study. Firstly, we studied a small, heterogeneous co-
hort with no control group given limitations of funding. Secondly, the difference in the tim-
ing of blood assessments, i.e. before dialysis in ‘over-hydrated’ HD patients versus in a ‘steady 
state’ in those on PD or with CKD may have led to differences between groups, although the 
impact is likely minor given that Faure et al.   [16]   have demonstrated that the concentration 
of endothelial-specific MPs is not different before and after the HD session. Furthermore, 
although hemoglobin was not typically drawn on the day PWV was performed, when we 
looked at the median hemoglobin level, it was deemed not different from hemoglobin drawn 
closest to the date of PWV measurement, and in such stable patients is unlikely to make a 
significant difference. Thirdly, our EMP levels were magnitudes below those observed in 
other studies. This was likely due to the fact that EMP levels were determined after a high-
speed centrifugation procedure that selectively removes the smallest and lightest end of the 
MP spectrum detected by flow cytometry, and guaranties the removal of residual platelets. 
Fourthly, we acknowledge that PWV does not equal vascular disease; it measures arterial 
stiffness and is itself a surrogate parameter for vascular disease. As it measures a composite 
value of both structural and functional aspects of arterial stiffness, it may not be constant 
over time, nor can the ‘functional’ component be assessed clinically. Lastly, we did not study 
the impact of ESAs that are known to have both endothelium-‘protective’ and -‘harmful’ ef-
fects. Reports to date have not demonstrated an association between PWV and ESA dose or 
ESA responsiveness, although all are small studies   [3, 21]  .
    In conclusion, while others have described a physiologic link between anemia, endothe-
lial dysfunction and arterial stiffness in CKD patients, we were not able to find this within 
a very stable population of CKD and dialysis patients. While our sample size is small, it is 199
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not significantly different from previous studies, so we would hypothesize that the stability 
and wellness of the population precluded demonstration of the relationships. The interaction 
between hemoglobin/ESA, vascular endothelium and inflammation remains complex, and 
given the amount of data supporting an association between these, efforts should be made 
to continue this line of investigation so that the relationships can be resolved.
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